Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force

Dirk Dressler, Roongroj Bhidayasiri, Saeed Bohlega, Abderrahmane Chahidi, Tae Mo Chung, Markus Ebke, L. Jorge Jacinto, Ryuji Kaji, Serdar Koçer, Petr Kanovsky, Federico Micheli, Olga Orlova, Sebastian Paus, Zvezdan Pirtosek, Maja Relja, Raymond L. Rosales, José Alberto Sagástegui-Rodríguez, Paul W. Schoenle, Gholam Ali Shahidi, Sofia TimerbaevaUwe Walter, Fereshte Adib Saberi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

© 2016, Springer-Verlag Berlin Heidelberg. Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.
Original languageEnglish
Pages (from-to)112-120
Number of pages9
JournalJournal of Neurology
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Botulinum Toxins
Movement Disorders
Advisory Committees
Multiple Sclerosis
Therapeutics
Stroke
Berlin
PubMed
Antibody Formation
Observational Studies
Publications
Randomized Controlled Trials
Guidelines
Recurrence

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Dressler, Dirk ; Bhidayasiri, Roongroj ; Bohlega, Saeed ; Chahidi, Abderrahmane ; Chung, Tae Mo ; Ebke, Markus ; Jacinto, L. Jorge ; Kaji, Ryuji ; Koçer, Serdar ; Kanovsky, Petr ; Micheli, Federico ; Orlova, Olga ; Paus, Sebastian ; Pirtosek, Zvezdan ; Relja, Maja ; Rosales, Raymond L. ; Sagástegui-Rodríguez, José Alberto ; Schoenle, Paul W. ; Shahidi, Gholam Ali ; Timerbaeva, Sofia ; Walter, Uwe ; Saberi, Fereshte Adib. / Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. In: Journal of Neurology. 2017 ; pp. 112-120.
@article{5376af85ccd04ac082bc8baa0e3d9f71,
title = "Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force",
abstract = "{\circledC} 2016, Springer-Verlag Berlin Heidelberg. Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.",
author = "Dirk Dressler and Roongroj Bhidayasiri and Saeed Bohlega and Abderrahmane Chahidi and Chung, {Tae Mo} and Markus Ebke and Jacinto, {L. Jorge} and Ryuji Kaji and Serdar Ko{\cc}er and Petr Kanovsky and Federico Micheli and Olga Orlova and Sebastian Paus and Zvezdan Pirtosek and Maja Relja and Rosales, {Raymond L.} and Sag{\'a}stegui-Rodr{\'i}guez, {Jos{\'e} Alberto} and Schoenle, {Paul W.} and Shahidi, {Gholam Ali} and Sofia Timerbaeva and Uwe Walter and Saberi, {Fereshte Adib}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s00415-016-8304-z",
language = "English",
pages = "112--120",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",

}

Dressler, D, Bhidayasiri, R, Bohlega, S, Chahidi, A, Chung, TM, Ebke, M, Jacinto, LJ, Kaji, R, Koçer, S, Kanovsky, P, Micheli, F, Orlova, O, Paus, S, Pirtosek, Z, Relja, M, Rosales, RL, Sagástegui-Rodríguez, JA, Schoenle, PW, Shahidi, GA, Timerbaeva, S, Walter, U & Saberi, FA 2017, 'Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force', Journal of Neurology, pp. 112-120. https://doi.org/10.1007/s00415-016-8304-z

Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. / Dressler, Dirk; Bhidayasiri, Roongroj; Bohlega, Saeed; Chahidi, Abderrahmane; Chung, Tae Mo; Ebke, Markus; Jacinto, L. Jorge; Kaji, Ryuji; Koçer, Serdar; Kanovsky, Petr; Micheli, Federico; Orlova, Olga; Paus, Sebastian; Pirtosek, Zvezdan; Relja, Maja; Rosales, Raymond L.; Sagástegui-Rodríguez, José Alberto; Schoenle, Paul W.; Shahidi, Gholam Ali; Timerbaeva, Sofia; Walter, Uwe; Saberi, Fereshte Adib.

In: Journal of Neurology, 01.01.2017, p. 112-120.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force

AU - Dressler, Dirk

AU - Bhidayasiri, Roongroj

AU - Bohlega, Saeed

AU - Chahidi, Abderrahmane

AU - Chung, Tae Mo

AU - Ebke, Markus

AU - Jacinto, L. Jorge

AU - Kaji, Ryuji

AU - Koçer, Serdar

AU - Kanovsky, Petr

AU - Micheli, Federico

AU - Orlova, Olga

AU - Paus, Sebastian

AU - Pirtosek, Zvezdan

AU - Relja, Maja

AU - Rosales, Raymond L.

AU - Sagástegui-Rodríguez, José Alberto

AU - Schoenle, Paul W.

AU - Shahidi, Gholam Ali

AU - Timerbaeva, Sofia

AU - Walter, Uwe

AU - Saberi, Fereshte Adib

PY - 2017/1/1

Y1 - 2017/1/1

N2 - © 2016, Springer-Verlag Berlin Heidelberg. Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.

AB - © 2016, Springer-Verlag Berlin Heidelberg. Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.

U2 - 10.1007/s00415-016-8304-z

DO - 10.1007/s00415-016-8304-z

M3 - Article

SP - 112

EP - 120

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -